Immunoglobulin variants and uses thereof
AssigneeGenentech, Inc.
InventorsCAMELLIA W. ADAMS, ANDREW C. CHAN, CRAIG W. CROWLEY, HENRY B. LOWMAN, GERALD R. NAKAMURA, LEONARD G. PRESTA
Life of this patent
Estimating the term…
Abstract
The invention provides humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases.
Claims78
A humanized antibody that binds human CD20, or an antigen-binding fragment thereof, the antibody comprising the heavy and light chain amino acid sequences of SEQ ID NO. 39 and 40, respectively.
2-8. (canceled)
A humanized antibody that binds human CD20, or an antigen-binding fragment thereof, wherein the antibody comprises the light and heavy chain amino acid sequence of SEQ ID NO. 40 and 41, respectively.
10-14. (canceled)
A humanized antibody that binds human CD20, or an antigen-binding fragment thereof, the antibody comprising the heavy and light chain amino acid sequences of SEQ ID NO. 39 and 40, respectively, further comprising at least one amino acid substitution in the Fc region that improves ADCC and/or CDC activity.
A humanized antibody that binds human CD20, or an antigen-binding fragment thereof, the antibody comprising the heavy and light chain amino acid sequences of SEQ ID NO. 39 and 40, respectively, further comprising at least one amino acid substitution in the Fc region that decreases CDC activity.
22-23. (canceled)
(canceled)
(canceled)
36-37. (canceled)
(canceled)
A method of treating an autoimmune disease selected from the group consisting of Dermatomyositis, Wegner's granulomatosis, ANCA vasculitis, Aplastic anemia, Autoimmune hemolytic anemia (AIHA), factor VIII deficiency, hemophilia A, Autoimmune neutropenia, Castleman's syndrome, Goodpasture's syndrome, solid organ transplant rejection, graft versus host disease (GVHD), IgM mediated, thrombotic thrombocytopenic purpura (TTP), Hashimoto's Thyroiditis, autoimmune hepatitis, lymphoid interstitial pneumonitis (HIV), bronchiolitis obliterans (non-transplant) vs. NSIP, Guillain-Barre Syndrome, large vessel vasculitis, giant cell (Takayasu's) arteritis, medium vessel vasculitis, Kawasaki's Disease, and polyarteritis nodosa, comprising administering to a patient suffering from the disease, a therapeutically effective amount of a CD20 binding antibody or functional fragment thereof.
59-60. (canceled)
62-67. (canceled)
(canceled)
A method of treating rheumatoid arthritis (RA) in a human subject comprising administering a CD20 antibody to the subject at a dosage selected from the group consisting of 2×50 mg, 2×200 mg, and 2×500 mg.
78-81. (canceled)
A humanized antibody that binds human CD20, or an antigen-binding fragment thereof, wherein the antibody comprises the heavy and light chain amino acid sequence of SEQ ID NO. 42 and 43, respectively.
A humanized antibody that binds human CD20, or an antigen-binding fragment thereof, wherein the antibody comprises the VH sequence of SEQ ID NO.51 and the VL sequence of SEQ ID NO.52.
A humanized antibody that binds human CD20, or an antigen-binding fragment thereof, wherein the antibody comprises the VH sequence of SEQ ID NO.51 and the VL sequence of SEQ ID NO.53.
Dependencies are inferred from the claim text.